clinical trial · NCT04908189
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
Bristol-Myers Squibb·phase3·active not recruiting·n = 729
Psoriatic ArthritisDeucravacitinibPlaceboApremilast
brief summary
The purpose of this study is to evaluate the safety and efficacy of deucravacitinib versus placebo for the treatment of participants with active PsA who are naïve to biologic disease modifying antirheumatic drugs or had previously received TNFα inhibitor treatment.The long term extension period will provide additional long-term safety and efficacy information.
started
Jul 15, 2021
primary completion
Nov 7, 2024
completion
Nov 12, 2026
last updated
Sep 11, 2026
official title
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol